Tirzepatide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tirzepatide
Accession Number
DB15171
Description

Tirzepatide is under investigation in clinical trial NCT03311724 (A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes).

Type
Biotech
Groups
Investigational
Purchasing individual compounds or compound libraries for your research?
Learn More
Synonyms
Not Available
External IDs
  • LY3298176

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Tirzepatide.
AcebutololThe therapeutic efficacy of Tirzepatide can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Tirzepatide can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Tirzepatide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Tirzepatide can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Tirzepatide.
AlbiglutideThe risk or severity of hypoglycemia can be increased when Albiglutide is combined with Tirzepatide.
AlclometasoneThe risk or severity of hyperglycemia can be increased when Alclometasone is combined with Tirzepatide.
AlogliptinThe risk or severity of hypoglycemia can be increased when Alogliptin is combined with Tirzepatide.
AmcinonideThe risk or severity of hyperglycemia can be increased when Amcinonide is combined with Tirzepatide.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
OYN3CCI6QE
CAS number
2023788-19-2

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentBMI >27 kg/m2 / BMI >30 kg/m21
3Active Not RecruitingTreatmentType 2 Diabetes Mellitus6
3CompletedTreatmentType 2 Diabetes Mellitus1
3RecruitingTreatmentType 2 Diabetes Mellitus3
2CompletedTreatmentType 2 Diabetes Mellitus2
2RecruitingTreatmentNonalcoholic Steatohepatitis1
1Active Not RecruitingBasic ScienceHealthy Volunteers1
1Active Not RecruitingBasic ScienceType 2 Diabetes Mellitus1
1CompletedBasic ScienceEnd Stage Renal Disease (ESRD) / Impaired kidney function1
1CompletedBasic ScienceHealthy Volunteers4

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 08:55 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates